Acadian Asset Management
LYEL icon

Acadian Asset Management’s Lyell Immunopharma LYEL Stock Holding History

Acadian Asset Management’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$836K Buy
+59,748
New +$1.08M ﹤0.01% 1312
2026
Q1 		– Sell
-1,657
Closed -$51K – 2158
2025
Q4 		$51K Sell
1,657
-9,733
-85% -$218K ﹤0.01% 1790
2025
Q3 		$184K Sell
11,390
-15,976
-58% -$182K ﹤0.01% 1415
2025
Q2 		$241K Sell
27,366
-5,679
-17% -$51.7K ﹤0.01% 1276
2025
Q1 		$354K Buy
33,045
+22,181
+204% +$272K ﹤0.01% 1146
2024
Q4 		$139K Buy
+10,864
New +$215K ﹤0.01% 1312
2024
Q2 		– Sell
-3,898
Closed -$173K – 1846
2024
Q1 		$173K Buy
+3,898
New +$167K ﹤0.01% 1205

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Acadian Asset Management's LYEL Position: Q2 2026 in Review

Acadian Asset Management opened a new position in Lyell Immunopharma (LYEL) in Q2 2026: 59,748 shares worth $836K. The stake represents ﹤0.01% of the portfolio and ranks #1312 among its holdings. This is a return to the name: Acadian Asset Management previously reported a position in LYEL as recently as Q4 2025.

Acadian Asset Management first reported a position in LYEL in Q1 2024 and has held it in 7 quarters since. 87 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

  • Acadian Asset Management held 59,748 shares of Lyell Immunopharma worth $836K as of Q2 2026.
  • Lyell Immunopharma was a new Acadian Asset Management position in Q2 2026.
  • Lyell Immunopharma made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1312 holding.
  • Acadian Asset Management first reported a position in Lyell Immunopharma in Q1 2024 and has held it in 7 quarters since.
  • 87 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.